Merck Opens Molybdenum Precursor Plant in Eumseong, South Korea, Aiming to Build Key Hub in Memory Materials Supply Chain

Merck opened a new molybdenum precursor production facility in South Korea to support advanced semiconductor manufacturing. The facility, part of Merck's strategy to integrate materials and delivery systems, aims to improve supply chain reliability and support customers in developing next-generation semiconductor technologies. Merck has invested significantly in South Korea, positioning it as a key hub for its semiconductor materials business.

Merck has started producing molybdenum at its Eumseong plant in Korea, targeting next-gen chips. The metal is being tested as a tungsten replacement in 3-D NAND flash. Merck plans to expand its use to DRAM and logic chips. The project is part of a 600 million euro investment in Korea, a key market for the company. Merck aims to capitalize on the growing demand from local chipmakers like Samsung and SK hynix.

Merck will build a molybdenum production facility in Eumseong, South Korea, to support next-gen semiconductor materials. The company aims to integrate local production with supply systems to meet customer needs. Merck forecasts growing demand for molybdenum in semiconductor manufacturing, though adoption rates may vary. The facility will produce specialty precursors for CVD and ALD processes, with a focus on mass production and stable supply.

The European Commission approved pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) for resectable muscle-invasive bladder cancer (MIBC). The approval, based on KEYNOTE-B15 trial data, shows improved 2-year event-free survival (79.4% vs 66.2%) and overall survival (86.9% vs 81.3%) compared to chemotherapy. The combination is approved for use regardless of cisplatin eligibility. According to Merck, this offers a chemotherapy-free treatment option for MIBC patients in the EU.

The European Commission approved Merck's (MRK) Keytruda combined with Pfizer/Astellas' Padcev for bladder cancer. MRK's dividend yield is 2.4% with a high payout ratio of 1.11, and its stock is 22.9% overvalued per GF Value. MRK's GF Score is 79, showing strong profitability but middling momentum and financial strength. Insiders sold $71.4M in shares, with mixed institutional sentiment.

The European Commission approved a combination of Merck's Keytruda and Pfizer/Astellas' Padcev for treating muscle-invasive bladder cancer. This is the first such approval in Europe for a PD-1 inhibitor. According to the companies, the regimen is intended for resectable cases.